Suda Limited (ASX:SUD) has established a clinical advisory board for SUD-001, its first-in-class oral spray of sumatriptan for the treatment of migraine headache.
The two leading headache specialists will provide advice and guidance on the pivotal development plan, which will be presented to the US FDA.
In March, the company raised $5.3 million through a heavily oversubscribed placement to add value to its patented oral sprays and supporting its expanding business development activities.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.
News: Suda Limited establishes clinical advisory board for migraine treatment
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
-0.005(3.13%) |
Mkt cap ! $163.0M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 15.5¢ | $324.3K | 2.016M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 100094 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 333024 | 2 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| ALA (ASX) Chart |